Experimental drug shows promise for some patients with advanced prostate cancer

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited—and time matters. As the disease progresses, the window for effective, less intensive treatments begins to close. A multi-institutional clinical trial led by researchers at the Medical University of South Carolina (MUSC) and Emory University tested whether an experimental drug could extend the effectiveness of existing therapies.